A study published in the U.K.’s Lancet has shown that Russia’s Sputnik V vaccine is 91.6% effective against symptomatic COVID-19 and 100% effective against severe and moderate disease during its phase 3 trials.
Of the 19,866 participants in the trial including 2,144 people over the age of 60, (14,964) received two doses of the vaccine and a quarter (4,902) were given a placebo.
After the first dose was administered, 16 were found in the vaccine group while 62 were found in the placebo group.
The results of the trial had shown that the vaccine had an efficacy of 91.6% and that no adverse side effects were reported.
Despite the positive reports of the trial, most of the subjects were Caucasian so there is no data yet on other ethnic groups.
“The development of the Sputnik V vaccine has been criticized for unseemly haste, corner-cutting, and an absence of transparency. But the outcome reported here is clear and the scientific principle of vaccination is demonstrated, which means another vaccine can now join the fight to reduce the incidence of COVID-19,” said Ian Jones and Polly Roy, the authors of the paper.
The authors of the Lancet paper pointed out the analysis only included symptomatic cases of Covid, and more work would need to be done to understand whether it stops even asymptomatic cases
Jones and Roy further added that more research would need to be done to understand whether it stops asymptomatic cases and prevent the transmission of the virus to vaccinated individuals.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.